Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)
Phase 2
- Conditions
- ICD10 Code L40.9 for Psoriasis
- Registration Number
- NCT05981118
- Lead Sponsor
- Wake Forest University Health Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Enrolling by invitation
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Inclusion Criteria:<br><br> 1. Adults (age 18+) with Fitzpatrick skin type 3 or higher who have been diagnosed with<br> ICD10 code L40.9 for psoriasis between [dates] at Atrium Health Wake Forest Baptist<br> Medical Center.<br><br> 2. Stable on other therapies such as biologics for at least 3 months before<br> randomization.<br><br>Exclusion Criteria:<br><br> 1. Lack of a diagnosis of psoriasis (ICD10 code L40.9) or Fitzpatrick skin type below<br> 3.<br><br> 2. Pigmentary changes that in the opinion of the investigator would compromise the<br> ability to assess the study outcomes.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Examine the degree of Post-inflammatory pigment alteration (PIPA) in both intervention Arms;Examine the degree of Post-inflammatory pigment alteration (PIPA) in both intervention Arms;Examine the degree of Post-inflammatory pigment alteration (PIPA) in both intervention Arms
- Secondary Outcome Measures
Name Time Method